Tag: pubmed

Turk J Gastroenterol. 2025 Oct 12;37(2):251-259. doi: 10.5152/tjg.2025.25248.

ABSTRACT

BACKGROUND/AIMS: Persistent dyspeptic symptoms are common during the proton pump inhibitor (PPI) washout period before Helicobacter pylori (H. pylori) testing. However, the role of rebamipide in symptom management during this interval remains unclear.

MATERIALS AND METHODS: This double-blind, randomized controlled trial enrolled 65 patients with H. pylori-associated dyspepsia or gastritis, randomized (1:1) to receive rebamipide (100 mg 3 times daily) or placebo for 4 weeks, following a 14-day eradication regimen. The primary outcome was the proportion of responders achieving a ≥25% reduction in pain symptom scores on the Severity of Dyspepsia Assessment scale at week 6. Secondary outcomes included changes in pain symptoms, non-pain symptoms, and dyspepsia-related health scores, as well as eradication rates and safety.

RESULTS: All patients completed the trial. Although the proportion of responders was higher in the rebamipide group (18 patients, 56.3% vs. 13 patients, 39.4%), this difference was not statistically significant (P = .17). Scores for pain, non-pain, and dyspepsia-related health improved similarly in both groups. Eradication rates were comparable (87.5% vs. 90.0%), and no serious adverse events were reported.

CONCLUSION: The responder rate was higher in the rebamipide group, but the difference did not reach statistical significance. The poten tial benefit of rebamipide as a rescue therapy during the PPI washout period before H. pylori testing warrants further investigation in larger trials. Cite this article as: Suksai N, Chueansuwan R, Yongsiri S, Witoon R, Juttuporn A. Rebamipide for managing dyspeptic symptoms during proton-pump inhibitor washout before Helicobacter pylori testing: A randomized, double-blind, placebo-controlled trial. Turk J Gastroenterol. 2026;37(2):251-259.

PMID:41669931 | DOI:10.5152/tjg.2025.25248

Turk J Gastroenterol. 2025 Aug 25;37(2):208-214. doi: 10.5152/tjg.2025.25265.

ABSTRACT

BACKGROUND/AIMS: This study aimed to compare the efficacy of bolus versus infusion administration of terlipressin in patients with acute esophageal variceal bleeding and to elucidate any differences in clinical outcomes between the 2 approaches.

MATERIALS AND METHODS: This prospective study included patients divided into 2 groups. Group 1 received a 2 mg intravenous (IV) bolus followed by 1 mg IV every 4 hours. Group 2 received a 1 mg IV bolus followed by a 4 mg terlipressin infusion over 24 hours. Clinical and laboratory parameters, hospitalization duration, need for blood product transfusion, rebleeding or mortality within 6 weeks, and drug related side effects were evaluated.

RESULTS: Among the 46 patients, 23 (50%) received terlipressin as an IV bolus (group 1), and 23 (50%) received it as an infusion (group 2). Treatment failure occurred in 4 patients (8.7%), all from group 1, though the difference was not statistically significant (P = .109). Six patients (13%) experienced rebleeding and death within 6 weeks, with no significant differences in clinical outcomes between the groups. No significant differences in creatinine and sodium levels were observed between the groups at baseline or at the end of treat ment (P = .654). Additionally, no difference in the incidence of portal vein thrombosis was noted between survivors and non-survivors (P = 1.000).

CONCLUSION: As no significant differences in efficacy or safety were observed between bolus and infusion administration, infusion ther apy may be preferred due to its potential benefits in patient comfort and ease of administration. Cite this article as: Şenkaya A, Çelik F, Kurtulmuş Akgün İ, et al. Terlipressin treatment for acute esophageal variceal bleeding: Bolus or infusion? Turk J Gastroenterol. 2026;37(2):208-214.

PMID:41669923 | DOI:10.5152/tjg.2025.25265

J Hypertens. 2026 Jan 30. doi: 10.1097/HJH.0000000000004255. Online ahead of print.

ABSTRACT

BACKGROUND: Peripheral artery disease (PAD), assessed via the ankle-brachial index (ABI), is a recognized form of hypertension-mediated organ damage (HMOD). While alternative ABI calculations have shown improved sensitivity for PAD detection, their prognostic utility in hypertensive populations remains unclear.

METHODS: In this prospective cohort study of 21 875 hypertensive individuals (ÉRV Study), we compared the prognostic performance of three ABI-based approaches: standard ABI using the higher ankle pressure (ABI-HIGH), ABI using the lower ankle pressure (ABI-LOW), and multivessel ABI scoring (number of vessels with ABI ≤0.90). The primary endpoint was all-cause mortality, assessed over a median follow-up of 5 years using interval-censored Cox regression.

RESULTS: PAD prevalence was 14.4% using ABI-HIGH and 28.3% using ABI-LOW, with 13.9% of patients identified only by the latter. All PAD definitions were independently associated with mortality. ABI-LOW as a continuous variable demonstrated the strongest association (hazard ratio 1.87; 95% CI, 1.63-2.16). Multivessel ABI showed a dose-response relationship with mortality. However, overall discrimination was modest: time-dependent AUCs ranged from 0.608 to 0.635 for ABI-based models alone. When added to clinical predictors, ABI metrics improved the AUC to a range from 0.763 to 0.780, with added predictive value between 6 and 11%.

CONCLUSION: In hypertensive individuals, ABI-LOW and multivessel scoring identify more PAD cases and are independently associated with mortality. However, their incremental value in mortality risk prediction is limited. Alternative ABI methods may assist in identifying higher risk subgroups warranting further vascular assessment.

PMID:41669913 | DOI:10.1097/HJH.0000000000004255

Epidemiol Psychiatr Sci. 2026 Feb 11;35:e10. doi: 10.1017/S2045796026100468.

ABSTRACT

AIMS: Off-label use of antipsychotics, often at low doses, is increasing. Exploring the link between individual antipsychotic treatment patterns, including low-dose continuous use, and cardiometabolic health is crucial to prevent long-term morbidity and mortality. The current retrospective study examined the prevalence of cardiometabolic medicine use among antipsychotic-users, and its association with their past antipsychotic treatment patterns.

METHODS: Using a 10% sample of the Australian national medicine dispensing claims data from 2022, we identified individuals aged 15-64 years with ≥2 antipsychotic dispensings (antipsychotic-users) and non-users. We extracted their past 5-year antipsychotic treatment patterns (dose, duration and use of multiple agents). Using Poisson regression and accounting for age and sex, we calculated adjusted prevalence ratios (aPR) and 95% confidence intervals (CI) for cardiometabolic medicine use (anti-diabetics, antihypertensives, lipid modifiers, anti-thrombotics) among antipsychotic-users versus non-users. We applied unsupervised hierarchical clustering analysis to identify common antipsychotic-cardiometabolic co-dispensing.

RESULTS: Use of any cardiometabolic medicine was more prevalent among antipsychotic-users (35.8%, n = 28,345) than non-users (26%, n = 1,106,610) yielding an aPR of 1.30 (CI 1.28-1.33). aPRs for the use of anti-diabetics, lipid modifiers and antihypertensives were the highest among the younger age groups between 20 and 49 years and among women. Clustering analysis revealed increased co-dispensing of antipsychotics and anti-diabetics including sulfonylureas, statins, platelet aggregation inhibitors and beta blockers. The prevalence of cardiometabolic medicine use was associated with higher antipsychotic doses (23-54%), treatment duration (12-37%) and use of multiple agents (51%) compared with non-users. However, the prevalence of cardiometabolic medicine use for continuous (≥1 year) low-dose use of aripiprazole, asenapine, brexpiprazole, chlorpromazine, lurasidone, olanzapine, periciazine and quetiapine was also elevated (13-43%).

CONCLUSIONS: Use of cardiometabolic medicines is increased among people on long-term antipsychotic treatment. These results highlight the need for active monitoring for cardiometabolic adverse effects, with antipsychotic cessation where possible, or timely interventions to limit morbidity.

PMID:41669909 | DOI:10.1017/S2045796026100468

Adv Sci (Weinh). 2026 Feb 11:e21531. doi: 10.1002/advs.202521531. Online ahead of print.

ABSTRACT

Long-read sequencing promises to unravel the complexity of polymorphic immune genes including HLA, KIR, IG, and TCR, yet existing tools fall short in accuracy and scope. Here, we present SpecImmune, the first unified computational framework to simultaneously genotype these genes alongside the intricate CYP family from long-read data. Employing an iterative graph-based haplotype reconstruction algorithm, SpecImmune delivers precise diploid assemblies for each locus from diverse data types. Validated on 1019 samples from the 1kGP ONT cohort, 42 PacBio CLR and 9 PacBio HiFi samples from HGSVC, and 47 PacBio HiFi plus 37 ONT samples from HPRC, SpecImmune achieved 98% four-field HLA typing accuracy, surpassing HLA*LA by 11% and SpecHLA by 12%. It also delivers robust KIR and germline IG/TCR genotyping and supports multi-locus CYP allele detection, positioning it among the first integrated long-read solutions across immune gene families. Beyond superior performance, SpecImmune uncovers elevated germline IG/TCR heterozygosity in African populations ( $p=9.45\times {10}^{–86}$ ) and, through 1kGP analysis, suggests widespread cross-family co-evolution, clustering immune genes into two functionally distinct communities: the Integrated Immune-Metabolic Community and the Adaptive Presentation Community. Additionally, it enables allele-specific drug dosing recommendations and offers flexible customization for new loci, advancing immunology, precision medicine, and evolutionary genomics.

PMID:41669879 | DOI:10.1002/advs.202521531

Biometrics. 2026 Jan 6;82(1):ujag014. doi: 10.1093/biomtc/ujag014.

ABSTRACT

Estimating the causal effect of a treatment or health policy with observational data can be challenging due to an imbalance of and a lack of overlap between treated and control covariate distributions. In the presence of limited overlap, researchers choose between (1) methods (e.g., inverse probability weighting) that imply traditional estimands but whose estimators are at risk of considerable bias and variance; and (2) methods (e.g., overlap weighting) which imply a different estimand by modifying the target population to reduce variance. We propose a framework for navigating the tradeoffs between variance and bias due to imbalance and a lack of overlap and the targeting of the estimand of scientific interest. We introduce a bias decomposition that encapsulates bias due to (1) the statistical bias of the estimator; and (2) estimand mismatch, i.e., deviation from the population of interest. We propose two design-based metrics and an estimand selection procedure that help illustrate the tradeoffs between these sources of bias and variance of the resulting estimators. Our procedure allows analysts to incorporate their domain-specific preference for preservation of the original research population versus reduction of statistical bias. We demonstrate how to select an estimand based on these preferences with an application to right heart catheterization data.

PMID:41669864 | DOI:10.1093/biomtc/ujag014

Biometrics. 2026 Jan 6;82(1):ujag011. doi: 10.1093/biomtc/ujag011.

ABSTRACT

A spatial sampling design determines where sample locations are placed in a study area to achieve precise estimates of population parameters. Many environmental variables have positive spatial associations, and spatially balanced designs perform well. The recently published dynamic assignment sampling (DAS) design draws spatially balanced master or over-samples in auxiliary spaces. This article proposes a new objective function for DAS to draw doubly balanced master or over-samples, where two balancing properties are satisfied: approximately balanced on auxiliary variables and spatially balanced. All we require is a measure of the distance between population units. Numerical results show that the method generates spatially balanced, balanced, or doubly balanced master or over-samples and compares favorably with established fixed sample size designs. We provide an example application using total aboveground biomass over a large study area in Eastern Amazonia, Brazil, and design-based variance estimators.

PMID:41669863 | DOI:10.1093/biomtc/ujag011

Biometrics. 2026 Jan 6;82(1):ujag009. doi: 10.1093/biomtc/ujag009.

ABSTRACT

Individually randomized trials allow participants to be included in a trial multiple times, with independent randomization at each inclusion. Often referred to as re-randomization designs, these trials have been shown to increase trial recruitment rates. Treatment effect estimators remain unbiased but are more precise than for designs with more participants but no repeat inclusions, but do rely on additional assumptions. Here, we introduce a new class of cluster randomized trial designs: repeated inclusion cluster randomized trials, where some clusters are randomized serially in the same trial. The trial in which clusters are initially included may have a standard cluster randomized design or a longitudinal variant, such as a cluster randomized crossover design. Allowing clusters to participate multiple times in the same trial could reduce the need to recruit new clusters; useful when cluster recruitment is difficult. Assuming a constant treatment effect across repeated inclusions, we show that when equal numbers of clusters and participants are included in each treatment group in each study period, power will be the same or higher as for a similar trial where clusters are not re-randomized but which has the same total number of measurements. Whether power is maintained or increased depends on the study design and the within-cluster correlation structure; increasing the number of within-cluster comparisons increases study power.

PMID:41669862 | DOI:10.1093/biomtc/ujag009

Circ Cardiovasc Interv. 2026 Feb 11:e015932. doi: 10.1161/CIRCINTERVENTIONS.125.015932. Online ahead of print.

ABSTRACT

BACKGROUND: Calcified nodules (CNs) represent a high-risk coronary lesion phenotype associated with target lesion revascularization (TLR). Although rotational atherectomy (RA) is an established treatment for calcified lesions, its benefit for CNs remains unclear. This study aimed to evaluate the impact of RA on TLR and to identify specific morphological features on intravascular ultrasound that may influence its therapeutic effect for CNs.

METHODS: In a substudy of the U-SCAN registry (Coronary Intravascular Ultrasound for Calcified Nodule), 348 patients with CNs identified by intravascular ultrasound who underwent percutaneous coronary intervention were analyzed. We excluded patients with in-stent restenosis, use of alternative debulking devices, failed device passage without RA, and poor image quality. The final analysis included 209 patients, stratified by RA use. Multivariable Cox proportional hazards models were used to identify predictors of TLR and assess treatment interactions across subgroups.

RESULTS: Among 209 patients, 79 patients (37.8%) underwent RA. During a median follow-up of 2.1 years (interquartile range, 0.4-4.9), TLR was required in 20 of 79 patients (25.3%) in the RA group and 41 of 130 patients (31.5%) in the non-RA group. After adjustment, RA independently predicted reduced TLR (hazard ratio, 0.34 [95% CI, 0.19-0.62], P<0.001). In addition, intravascular ultrasound-derived calcification features, including greater lumen area stenosis, longer CN length, smaller final minimum lumen area, and adjacent circumferential calcification, were significantly associated with TLR. Notably, the benefit of RA on TLR was pronounced in patients with contralateral calcification (8.6% versus 51.6%, P<0.001). In contrast, without this feature, the TLR rate was higher in the RA group (38.6% versus 25.3%, P=0.11), resulting in a statistically significant interaction (P_interaction<0.001).

CONCLUSIONS: In patients with CNs, RA was associated with a reduced long-term risk of TLR. The presence of contralateral calcification identifies a subgroup deriving substantial benefit, supporting a more selective, morphology-guided approach to treatment.

REGISTRATION: URL: https://jrct.mhlw.go.jp/; Unique identifier: jRCT1050240037.

PMID:41669840 | DOI:10.1161/CIRCINTERVENTIONS.125.015932

Circulation. 2026 Feb 11. doi: 10.1161/CIR.0000000000001401. Online ahead of print.

ABSTRACT

Risk prediction has been used in the primary prevention of cardiovascular disease for >3 decades. Contemporary cardiovascular risk assessment relies on multivariable models, which integrate established cardiovascular risk factors and have evolved over time from the Framingham Risk Model to the pooled cohort equations to the PREVENT (Predicting Risk of CVD Events) equations. Recent scientific (ie, genomics, proteomics, metabolomics) and methodologic (ie, artificial intelligence) advances have led to a proliferation of novel models, biomarkers, and tools for potential use in risk prediction. In parallel, the growing armamentarium of preventive therapies, some with considerable cost, underscores the need for more accurate and precise risk assessment to prioritize those at highest risk who will derive the greatest absolute benefit. Accompanying the considerable enthusiasm for the potential of newer approaches to improve risk prediction is the need for rigorous evaluation and assessment of their performance (ie, accuracy, precision, incremental performance when added to contemporary multivariable risk models or established risk factors) and clinical utility (ie, actionability, scalability, generalizability) before adoption in clinical practice. Additional considerations in risk tool evaluation include reproducibility, cost-value considerations (including impact on downstream health care costs), and implications for health equity. This scientific statement defines a standardized framework for general considerations in risk prediction, statistical assessment of predictive utility, and critical appraisal of clinical utility and readiness. This scientific statement is intended to support clinicians, researchers, and policymakers in how best to evaluate current and emerging risk prediction tools and ultimately improve the prevention of cardiovascular disease in diverse populations.

PMID:41669831 | DOI:10.1161/CIR.0000000000001401